Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target
Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic
acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor …
acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor …
Pancreatic cancer
C Güngör, BT Hofmann… - British journal of …, 2014 - Wiley Online Library
In recent years, it has become clear that the current standard therapeutic options for
pancreatic cancer are not adequate and still do not meet the criteria to cure patients …
pancreatic cancer are not adequate and still do not meet the criteria to cure patients …
Midkine: a promising molecule for drug development to treat diseases of the central nervous system
T Muramatsu - Current pharmaceutical design, 2011 - ingentaconnect.com
Midkine (MK) is a heparin-binding cytokine, and promotes growth, survival, migration and
other activities of target cells. After describing the general properties of MK, this review …
other activities of target cells. After describing the general properties of MK, this review …
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma
WJ Van Houdt, YS Haviv, B Lu, M Wang… - Journal of …, 2006 - thejns.org
Object Malignant brain tumors have been proved to be resistant to standard treatments and
therefore require new therapeutic strategies. Survivin, a recently described member of the …
therefore require new therapeutic strategies. Survivin, a recently described member of the …
Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK)
J Luo, X Wang, Z Xia, L Yang, Z Ding… - Molecular Biology of …, 2015 - Am Soc Cell Biol
Midkine (MDK) expression is associated with the proliferation of many cancers, including
glioma. However, the upstream signaling that leads to MDK accumulation remains elusive …
glioma. However, the upstream signaling that leads to MDK accumulation remains elusive …
Impact of autophagy in oncolytic adenoviral therapy for cancer
H Tazawa, S Kuroda, J Hasei, S Kagawa… - International journal of …, 2017 - mdpi.com
Oncolytic virotherapy has recently emerged as a promising strategy for inducing tumor-
specific cell death. Adenoviruses are widely and frequently used in oncolytic virotherapy …
specific cell death. Adenoviruses are widely and frequently used in oncolytic virotherapy …
Bone and soft-tissue sarcoma: a new target for telomerase-specific oncolytic virotherapy
H Tazawa, J Hasei, S Yano, S Kagawa, T Ozaki… - Cancers, 2020 - mdpi.com
Adenovirus serotype 5 (Ad5) is widely and frequently used as a virus vector in cancer gene
therapy and oncolytic virotherapy. Oncolytic virotherapy is a novel antitumor treatment for …
therapy and oncolytic virotherapy. Oncolytic virotherapy is a novel antitumor treatment for …
The role of midkine in health and disease
EE Neumaier, V Rothhammer… - Frontiers in …, 2023 - frontiersin.org
Midkine (MDK) is a neurotrophic growth factor highly expressed during embryogenesis with
important functions related to growth, proliferation, survival, migration, angiogenesis …
important functions related to growth, proliferation, survival, migration, angiogenesis …
Midkine: a novel prognostic biomarker for cancer
H Jono, Y Ando - Cancers, 2010 - mdpi.com
Since diagnosis at an early stage still remains a key issue for modern oncology and is
crucial for successful cancer therapy, development of sensitive, specific, and non-invasive …
crucial for successful cancer therapy, development of sensitive, specific, and non-invasive …
Cancer stem cells: the final frontier for glioma virotherapy
Cancer stem cells (CSC) are a very small subset of all cancer cells and possess
characteristics very similar to normal stem cells, in particular, the capacity for self-renewal …
characteristics very similar to normal stem cells, in particular, the capacity for self-renewal …